TriangleDISEASE & TREATMENT SETTING
Imlygic: unresectable recurrent Melanoma after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Broader topic: Melanoma
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- unresectable
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after initial surgery
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Imlygic (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Study evidence for this setting
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Ipilimumab and Local Radiation for Selected Solid Tumors
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Mel
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice